Olema Pharmaceuticals (OLMA) Return on Capital Employed (2021 - 2026)
Olema Pharmaceuticals' (OLMA) quarterly Return on Capital Employed came in at 41.62% in Q1 2026, down 630.0% year-on-year from 7.85% in Q1 2025, and up 8.9% on a QoQ basis from 45.69% in Q4 2025.
Olema Pharmaceuticals (OLMA) Return on Capital Employed (2021 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has 6 years of Return on Capital Employed data on file, last reported at 41.62% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 630.0% year-over-year to 41.62% in Q1 2026; TTM through Mar 2026 was 41.62%, a 630.0% decrease from a year earlier, with the FY2025 full-year figure at 40.58%, up 358.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 41.62%, up from 45.69% in the prior quarter.
- Over the last five years, Return on Capital Employed for OLMA reached as high as 27.67% in Q1 2022 and fell as low as 64.21% in Q3 2024.
- Historically, Return on Capital Employed has averaged 46.7% across 5 years, with a median of 45.69% in 2025.
- Across the five-year window, Return on Capital Employed plunged 3317 bps in 2023 and surged 1590 bps in 2024, its largest moves.
- Year by year, Return on Capital Employed stood at 51.62% in 2022, then advanced by 23 bps to 39.87% in 2023, then fell by 19 bps to 47.61% in 2024, then climbed by 4 bps to 45.69% in 2025, then increased by 9 bps to 41.62% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 41.62% in Q1 2026, 45.69% in Q4 2025, and 50.8% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Olema Pharmaceuticals | 1.21 Bn | 1.21 Bn | - | -41.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.62% |
| Dec 31, 2025 | -45.69% |
| Sep 30, 2025 | -50.80% |
| Jun 30, 2025 | -43.33% |
| Mar 31, 2025 | -35.32% |
| Dec 31, 2024 | -47.61% |
| Sep 30, 2024 | -64.21% |
| Jun 30, 2024 | -52.29% |
| Mar 31, 2024 | -44.94% |
| Dec 31, 2023 | -39.87% |
| Sep 30, 2023 | -46.42% |
| Jun 30, 2023 | -59.14% |
| Mar 31, 2023 | -60.84% |
| Dec 31, 2022 | -51.62% |
| Sep 30, 2022 | -44.38% |
| Jun 30, 2022 | -38.17% |
| Mar 31, 2022 | -27.67% |
| Dec 31, 2021 | -23.62% |
| Sep 30, 2021 | -19.49% |
| Jun 30, 2021 | -15.68% |